MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device
Breakthrough Technology for Low-Cost Early Detection
of Cardiac Dysfunction in the Diastolic Phase
HeartSciences’ MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device is a new resting 12-lead electrocardiograph. It uses continuous wavelet transform (CWT) signal processing to provide new frequency and energy information to detect cardiac relaxation abnormalities associated with Left Ventricular Diastolic Dysfunction (LVDD). Extensive research confirms that almost all forms and co-morbidities of heart disease are associated with LVDD including hypertension, diabetes, valvular disease, ischemia, and reduced systolic function.
The MyoVista wavECG Device is an innovative advancement for low-cost electrocardiographic testing designed to provide physicians with new information to improve patient risk-assessment related to heart disease. This additional risk stratification information assists physicians in determining whether a patient should receive further testing, evaluation and/or treatment. In addition to wavECG Information, the MyoVista Device also provides all the information and capabilities of a full-featured conventional resting 12-lead ECG within the same test, at comparable cost, and following the same clinical AHA/IEC lead placement protocol.
Intuitive Touch Screen Interface
The MyoVista wavECG Device features a high definition touch screen which displays the proprietary MyoVista Energy Waveform, MyoVista Wavelet Analysis (Repolarization Algorithm), and MyoVista Ventricular Indices. It also provides all of the conventional information and interpretive analysis you would expect from a full-featured ECG. The high definition (1920 x 1080) touch screen has easy to use and intuitive features commonly associated with a tablet device. The MyoVista wavECG Device follows conventional AHA/IEC resting 12-lead placement protocols, thereby minimizing training requirements
Wavelet Signal Processing wavECG Information
The MyoVista wavECG Device uses continuous wavelet transform mathematics to display and analyze the myocardial energy detected during the cardiac cycle, with particular emphasis on repolarization. This new wavECG Information is designed to provide the physician with additional insights and information that can be used as part of an overall risk assessment and determination of the clinical pathway. LVDD is associated with almost all types of ischemic and structural heart disease.
MyoVista Energy Waveform
The MyoVista Energy Waveform graphically displays the energy distribution pattern of the heart’s electrical activity during each phase of the cardiac cycle. It is visually aligned with the conventional ECG trace and provided on a lead by lead basis.
The MyoVista Energy Waveform is displayed as a color scale (scalogram) and represents the ECG signal after transformation using continuous wavelet transform mathematics. The scalogram provides a non-linear mapping of energy and depicts the relative level of energy detected from the heart at each point in time and frequency. The MyoVista Energy Waveform visually aligns with the conventional ECG trace for easy analysis on a lead by lead basis.
MyoVista Ventricular Indices
The MyoVista Ventricular Indices represent the percentage of energy in relation to the peak energy detected during the cardiac cycle (usually close to or at an R-Wave peak). There are four Index values provided, as well as numeric comparisons (differences and ratios) for these four measurements. The right ventricle indices are an average of V1 and V2 leads, and the left ventricle indices are an average of V4, V5, and V6 leads.
MyoVista Wavelet Analysis, Algorithms and Statements
The MyoVista Wavelet Analysis, Algorithms and Statements provide the results of the Wavelet Analysis (with inputs from the MyoVista Energy Classification and MyoVista Ventricular Indices, as well as other conventional measures such as T-Axis, sex, and age) and provides statements which can be used to assist physicians in the assessment of patients having relaxation abnormalities associated with LV diastolic dysfunction that may require further clinical testing, evaluation and/or treatment.
Conventional ECG Trace with
The MyoVista wavECG Device provides conventional ECG trace information as well as the University of Glasgow 12-lead ECG Interpretive Analysis Algorithm that has more than 35 years of history and is considered one of the world’s leading ECG interpretive algorithms in the world.